Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
116.29 USD | +0.90% | -1.20% | +6.79% |
09-12 | Merck Says Health Canada Approved Keytruda as Treatment for Hard-to-Treat Solid Tumors | MT |
09-11 | Merck: positive results for HPV vaccine | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Goldman Sachs Adjusts Price Target on Merck & Company to $140 From $145, Maintains Buy Rating